Predictive value of comorbidity and anemia on outcome in patients with sinonasal carcinoma

Publication date: August 2018

Source: Journal of Cranio-Maxillofacial Surgery, Volume 46, Issue 8

Author(s): Christoph Becker, Kilian Konrad Kenjiro Dahlem, Kitty Lange, Manuel Christoph Ketterer, Jens Pfeiffer

Abstract

Introduction

To evaluate the influence of comorbidities and anemia on outcome and survival in patients with sinonasal carcinomas.

Materials and Methods

Review of medical records of 121 patients with carcinoma treated at a single quaternary medical care and cancer center between 2002 and 2015. Comorbidities were classified according to the age-adjusted Charlson comorbidity index (ACCI) scoring system.

Results

71 patients were male, 50 were female. Median age was 65 years, and the median interval between tumor diagnosis and date of study inclusion was 71 months. The most common histological subtype was squamous cell carcinoma (n = 64). The median ACCI score was 2 and the most frequent ACCI score was 0 (n = 26). Mean overall survival was 52.2 months (ACCI 0–2) and 39.5 months (ACCI ≥ 3), respectively (p < 0.0001). Mean disease-free survival was 52.9 months (ACCI 0–2) and 45.5 months (ACCI ≥ 3), respectively (p = 0.026). Mean overall survival in patients without anemia was 49.5 months, compared with 39.8 months in patients with anemia (p = 0.043).

Conclusion

Comorbidity is an independent risk factor on overall, disease-free and disease-specific survival in patients with sinonasal carcinoma. Anemia is associated with shorter overall survival. This is the first study evaluating comorbidity using the ACCI scoring system and focusing on patients with sinonasal carcinoma.

https://ift.tt/2LKz3wX